The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01706939
Recruitment Status : Active, not recruiting
First Posted : October 15, 2012
Last Update Posted : April 3, 2018
The Biodesign Institute
Arizona State University
Information provided by (Responsible Party):
Marshall Posner, Icahn School of Medicine at Mount Sinai

No Study Results Posted on for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : December 2021
  Estimated Study Completion Date : December 2021
Forastiere A, Maor M, Weber R, Pajak, T, Glisson B, Trotti A, Ridge J, et al. Long term results of Intergroup RTOG 91-11: A Phase III trial to preserve the larynx - Induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. Proceedings of the American Society of Clinical Oncology. 2006:5517.

Publications automatically indexed to this study by Identifier (NCT Number):